The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews

Clinical Neurology and Neurosurgery

Volumn 110, Issue 9, 2008, Pages 878-885

  Clerico, Marinella ^a   Rivoiro, Chiara ^a   Contessa, Giulia ^a   Viglietti, Daniela ^a   Durelli, Luca ^a  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Evidence based medicine; Immunomodulatory treatments; Immunosuppressory treatments evidence based medicine; Multiple sclerosis; Systematic reviews

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PLACEBO;

CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MULTIPLE SCLEROSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MITOXANTRONE; MULTIPLE SCLEROSIS; PEPTIDES;

EID: 53549118637     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2007.10.020     Document Type: Review

References (30)

1. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
2. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39 (1996) 285-294 [Erratum in: Ann Neurol 1996 Sep;40(3):480]
3. Randomised, double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-504.
4. Altman D.G., Schulz K.F., Moher D., Egger M., Davidoff F., and Elbourne D. CONSORT GROUP (Consolidated Standards of Reporting Trials). The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134 8 (2001) 663-694 [Review]
5. Filippini G., Munari L., Incorvaia B., Ebers G.C., Polman C., D'Amico R., et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361 9357 (2003) 545-552
6. Sackett D.L., Richardson W.S., Rosemberg W., and Haynes R.B. Evidence-based medicine. How to practice and teach EBM (1997), Churchill Livingstone, London
7. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 120 (1997) 865-916
8. Paty D.W., and Li D.K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 662-667
9. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995;45(7):1277-85.
10. Rudick R.A., Goodkin D.E., Jacobs L.D., Cookfair D.L., Herndon R.M., Richert J.R., et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis.The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 49 2 (1997) 358-363
11. Simon J.H., Jacobs L.D., Campion M., Wende K., Simonian N., Cookfair D.L., et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 43 1 (1998) 79-87
12. Li D.K., and Paty D.W. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis. Ann Neurol 46 (1999) 197-206
13. Durelli L., Verdun E., Barbero P., Bergui M., Versino E., Ghezzi A., et al., Independent Comparison of Interferon (INCOMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359 9316 (2002) 1453-1460
14. Panitch H., Goodin D.S., Francis G., Chang P., Coyle P.K., O'Connor P., and Evidence study group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59 (2002) 1496-1506
15. Weinshenker B.G., Rice G.P., Noseworthy J.H., Carriere W., Baskerville J., and Ebers G.C. The natural history of multiple sclerosis: a geographically based study 3. Multivariate analysis of predictive factors and models of outcome. Brain 114 Pt 2 (1991) 1045-1056
16. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. New Eng J Med 343 13 (2000) 898-904
17. Comi G., Filippi M., Barkhof F., Durelli L., Edan G., Fernández O., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 357 9268 (2001) 1576-1582
18. Kappos L., Polman C.H., Freedman M.S., Edan G., Hartung H.P., Miller D.H., et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67 7 (2006) 1242-1249
19. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., et al. New diagnostic Criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13 3 (1983) 227-231
20. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45 7 (1995) 1268-1276
21. Calabresi P.A., Stone L.A., Bash C.N., Frank J.A., and McFarland H.F. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology 48 5 (1997) 1446-1448
22. Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis (Cochrane Review). In: The Cochrane Library, Issue 4. Chichester, UK: John Wiley and Sons, Ltd.; 2004. p. 1-28.
23. Martinelli Boneschi F., Rovaris M., Johnson K.P., Miller A., Wolinsky J.S., Ladkani, et al. Effect of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult Scler 9 4 (2003) 349-355
24. Mittal Y. Homogeneity of subpopulations and Simpson's Paradox. J Am Stat Assoc 86 (1991) 167-172
25. Edan G., Miller D., Clanet M., Confavreux C., Lyon-Caen O., Lubetzki C., et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomized multicenter study of active disease using MRI and clinical criteria. J Neurosurg Psychiatry 62 2 (1997) 112-118
26. Hartung H.P., Gonsette R., König N., Kwiecinski H., Guseo A., Morrissey S.P., et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicentre trial. Lancet 360 9350 (2002) 2018-2025
27. Goodin D.S., Arnason B.G., Coyle P.K., Frohman E.M., and Paty D.W. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 61 (2003) 1332-1338
28. Kleinschmidt-DeMasters B.K., and Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with Natalizumab and interferon beta 1 a for multiple sclerosis. New Eng J Med 353 (2005) 1-6
29. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., et al. AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New Eng J Med 354 9 (2006) 899-910
30. Rudick R.A., Stuart W.H., Calabresi P.A., Confavreux C., Galetta S.L., Radue E.W., et al. SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New Eng J Med 354 9 (2006) 911-923